TY - JOUR
T1 - Molecular spectrum and differential diagnosis in patients referred with sporadic or autosomal recessive osteogenesis imperfecta
AU - Caparros-Martin, Jose A.
AU - Aglan, Mona S.
AU - Temtamy, Samia
AU - Otaify, Ghada A.
AU - Valencia, Maria
AU - Nevado, Julián
AU - Vallespin, Elena
AU - Del Pozo, Angela
AU - Prior de Castro, Carmen
AU - Calatrava-Ferreras, Lucia
AU - Gutierrez, Pilar
AU - Bueno, Ana M.
AU - Sagastizabal, Belen
AU - Guillen-Navarro, Encarna
AU - Ballesta-Martinez, Maria
AU - Gonzalez, Vanesa
AU - Basaran, Sarenur Y.
AU - Buyukoglan, Ruksan
AU - Sarikepe, Bilge
AU - Espinoza-Valdez, Cecilia
AU - Cammarata-Scalisi, Francisco
AU - Martinez-Glez, Victor
AU - Heath, Karen E.
AU - Lapunzina, Pablo
AU - Ruiz-Perez, Victor L.
N1 - Funding Information:
We thank the patients and their families for their participation in this study. We also thank the NHLBI GO Exome Sequencing Project and its ongoing studies which produced and provided exome variant calls for comparison: the Lung GO Sequencing Project (HL-102923), the WHI Sequencing Project (HL-102924), the Broad GO Sequencing Project (HL-102925), the Seattle GO Sequencing Project (HL-102926), and the Heart GO Sequencing Project (HL-103010). This work was funded by the Spanish Ministry of Economy and Competitiveness [SAF2013-43365-R] and CIBERER (ER14-PR04-ACCI13-760). None of the authors have a conflict interest related to this work.
Publisher Copyright:
© 2016 The Authors. Molecular Genetics & Genomic Medicine published by Wiley Periodicals, Inc.
PY - 2017/1
Y1 - 2017/1
N2 - Background: Osteogenesis imperfecta (OI) is a heterogeneous bone disorder characterized by recurrent fractures. Although most cases of OI have heterozygous mutations in COL1A1 or COL1A2 and show autosomal dominant inheritance, during the last years there has been an explosion in the number of genes responsible for both recessive and dominant forms of this condition. Herein, we have analyzed a cohort of patients with OI, all offspring of unaffected parents, to determine the spectrum of variants accounting for these cases. Twenty patients had nonrelated parents and were sporadic, and 21 were born to consanguineous relationships. Methods: Mutation analysis was performed using a next-generation sequencing gene panel, homozygosity mapping, and whole exome sequencing (WES). Results: Patients offspring of nonconsanguineous parents were mostly identified with COL1A1 or COL1A2 heterozygous changes, although there were also a few cases with IFITM5 and WNT1 heterozygous mutations. Only one sporadic patient was a compound heterozygote for two recessive mutations. Patients offspring of consanguineous parents showed homozygous changes in a variety of genes including CRTAP, FKBP10, LEPRE1, PLOD2, PPIB, SERPINF1, TMEM38B, and WNT1. In addition, two patients born to consanguineous parents were found to have de novo COL1A1 heterozygous mutations demonstrating that causative variants in the collagen I structural genes cannot be overlooked in affected children from consanguineous couples. Further to this, WES analysis in probands lacking mutations in OI genes revealed deleterious variants in SCN9A, NTRK1, and SLC2A2, which are associated with congenital indifference to pain (CIP) and Fanconi–Bickel syndrome (FBS). Conclusion: This work provides useful information for clinical and genetic diagnosis of OI patients with no positive family history of this disease. Our data also indicate that CIP and FBS are conditions to be considered in the differential diagnosis of OI and suggest a positive role of SCN9A and NTRK1 in bone development.
AB - Background: Osteogenesis imperfecta (OI) is a heterogeneous bone disorder characterized by recurrent fractures. Although most cases of OI have heterozygous mutations in COL1A1 or COL1A2 and show autosomal dominant inheritance, during the last years there has been an explosion in the number of genes responsible for both recessive and dominant forms of this condition. Herein, we have analyzed a cohort of patients with OI, all offspring of unaffected parents, to determine the spectrum of variants accounting for these cases. Twenty patients had nonrelated parents and were sporadic, and 21 were born to consanguineous relationships. Methods: Mutation analysis was performed using a next-generation sequencing gene panel, homozygosity mapping, and whole exome sequencing (WES). Results: Patients offspring of nonconsanguineous parents were mostly identified with COL1A1 or COL1A2 heterozygous changes, although there were also a few cases with IFITM5 and WNT1 heterozygous mutations. Only one sporadic patient was a compound heterozygote for two recessive mutations. Patients offspring of consanguineous parents showed homozygous changes in a variety of genes including CRTAP, FKBP10, LEPRE1, PLOD2, PPIB, SERPINF1, TMEM38B, and WNT1. In addition, two patients born to consanguineous parents were found to have de novo COL1A1 heterozygous mutations demonstrating that causative variants in the collagen I structural genes cannot be overlooked in affected children from consanguineous couples. Further to this, WES analysis in probands lacking mutations in OI genes revealed deleterious variants in SCN9A, NTRK1, and SLC2A2, which are associated with congenital indifference to pain (CIP) and Fanconi–Bickel syndrome (FBS). Conclusion: This work provides useful information for clinical and genetic diagnosis of OI patients with no positive family history of this disease. Our data also indicate that CIP and FBS are conditions to be considered in the differential diagnosis of OI and suggest a positive role of SCN9A and NTRK1 in bone development.
KW - Bone development
KW - congenital indifference to pain
KW - Fanconi–Bickel syndrome
KW - osteogenesis imperfecta
UR - http://www.scopus.com/inward/record.url?scp=85040525707&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85040525707&partnerID=8YFLogxK
U2 - 10.1002/mgg3.257
DO - 10.1002/mgg3.257
M3 - Article
AN - SCOPUS:85040525707
SN - 2324-9269
VL - 5
SP - 28
EP - 39
JO - Molecular genetics & genomic medicine
JF - Molecular genetics & genomic medicine
IS - 1
ER -